Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Non Operating Income (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Other Non Operating Income for 6 consecutive years, with -$21000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non Operating Income fell 2000.0% to -$21000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$36000.0, a 46.27% increase, with the full-year FY2024 number at -$77000.0, up 57.46% from a year prior.
  • Other Non Operating Income was -$21000.0 for Q3 2025 at 4D Molecular Therapeutics, up from -$61000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $67000.0 in Q1 2025 to a low of -$158000.0 in Q3 2023.
  • A 5-year average of -$25176.5 and a median of -$13000.0 in 2021 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: plummeted 2075.0% in 2023, then surged 770.0% in 2025.
  • 4D Molecular Therapeutics' Other Non Operating Income stood at -$7000.0 in 2021, then surged by 142.86% to $3000.0 in 2022, then tumbled by 466.67% to -$11000.0 in 2023, then crashed by 90.91% to -$21000.0 in 2024, then changed by 0.0% to -$21000.0 in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Other Non Operating Income are -$21000.0 (Q3 2025), -$61000.0 (Q2 2025), and $67000.0 (Q1 2025).